Potential application of IDH1 and IDH2 mutations as prognostic indicators in non-promyelocytic acute myeloid leukemia: a meta-analysis

References

• Sabattini E, Bacci F, Sagramoso C, . WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010;102:83–87.
   PubMedGoogle Scholar
• Dohner H, Estey EH, Amadori S, . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Chou WC, Lei WC, Ko BS, . The prognostic impact and stability of isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 2011;25:246–253.
   PubMed Web of Science ®Google Scholar
• Chou WC, Hou HA, Chen CY, . Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010;115:2749–2754.
   PubMed Web of Science ®Google Scholar
• Jeziskova I, Razga F, Bajerova M, . IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status. Leuk Lymphoma 2010;51:2285–2287.
   PubMed Web of Science ®Google Scholar
• Rockova V, Abbas S, Wouters BJ, . Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 2011; 118:1069–1076.
   PubMed Web of Science ®Google Scholar
• Thol F, Damm F, Wagner K, . Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010;116:614–616.
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Oxman AD, Vist GE, . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924–926.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088–1101.
   PubMed Web of Science ®Google Scholar
• Hou HA, Kuo YY, Liu CY, . DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and the clinical implication. Blood 2012;119:559–568.
   PubMed Web of Science ®Google Scholar
• Boissel N, Nibourel O, Renneville A, . Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol 2010;28:3717–3723.
   PubMed Web of Science ®Google Scholar
• Lin J, Yao DM, Qian J, . IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 2012;91:519–525.
   PubMed Web of Science ®Google Scholar
• Green CL, Evans CM, Hills RK, . The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 2010;116:2779–2782.
   PubMed Web of Science ®Google Scholar
• Green CL, Evans CM, Zhao L, . The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 2011;118:409–412.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, . DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424–2433.
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, . IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636–3643.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Haferlach C, Ulke M, . IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010;116:5486–5496.
   PubMed Web of Science ®Google Scholar
• Wagner K, Damm F, Gohring G, . Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol 2010;28:2356–2364.
   PubMed Web of Science ®Google Scholar
• Caramazza D, Lasho TL, Finke CM, . IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 2010;24:2120–2122.
   PubMed Web of Science ®Google Scholar
• Gross S, Cairns RA, Minden MD, . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010;207:339–344.
   PubMed Web of Science ®Google Scholar
• Reitman ZJ, Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010;102:932–941.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, . Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553–567.
   PubMed Web of Science ®Google Scholar
• Trachootham D, Zhou Y, Zhang H, . Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006;10:241–252.
   PubMed Web of Science ®Google Scholar
• Katz MS. Therapy insight: potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2005;2:82–89.
   PubMedGoogle Scholar